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TRAIL or tumor necrosis factor (TNF) related apoptosis-inducing ligand is a member of the TNF superfamily of proteins, whose
best characterized function is the induction of apoptosis in tumor, infected, or transformed cells through activation of specific
receptors. In nontransformed cells, however, the actions of TRAIL are less well characterized. Recent studies suggest that TRAIL
may be implicated in the development and progression of diabetes. Here we review TRAIL biological actions, its effects on the
immune system, and how and to what extent it has been shown to protect against diabetes.
1. Introduction
TRAIL or tumor necrosis factor (TNF) related apoptosis-
inducing ligand is a member of the TNF superfamily of
proteins, whose best characterized function is the induction
of apoptosis in tumor, infected, or transformed cells through
activation of specific receptors. There is accumulating evi-
dence showing that TRAIL-induced apoptosis is not limited
to transformed cells but may be also induced in primary cells,
such as immune cells. TRAIL seems in fact involved in the
regulation of various physiological and pathological pro-
cesses of the innate and adaptive immune system.
Diabetes mellitus (DM) is a heterogeneous clinical syn-
drome featured by high levels of glucose. Whether it is type
1 DM (T1DM) or type 2 DM (T2DM) the immune system is
involved in the development and progression of both. Inter-
estingly, animal studies suggest that TRAIL might protect
against diabetes development and progression. The multiple
mechanisms underlying TRAIL protective effects against DM
may involve not only TRAIL proapoptotic actions on autore-
active T cells but also the promotion of T regulatory cells,
as well as newly characterized antiadipogenic and anti-
inflammatory actions. Here we review TRAIL biological
functions, its effects on the immune system, and how and to
what extent it has been shown to protect against diabetes.
2. Overview on TRAIL Biology
2.1. TRAILBiology. For a single-cell organism, lifewithmuta-
tions is apparently better thanno life at all, but inmulticellular
organisms the health of the organism takes precedence over
the life of an individual cell and, thus, when cells are damaged,
altered, or they become unnecessary, they do not con-
tinue division but instead “commit suicide” by undergoing
apoptosis. Apoptosis is a process leading to cell death,
whereby unrequired cells can be eliminated in order to safe-
guard multicellular organism health. There are two ways of
signalling leading to apoptosis. One is called “intrinsic path-
way,” because it is triggered by an intracellular signal, such
as DNA damage, while the other is called “extrinsic pathway,”
because it is triggered by an extracellular signal, which usually
derives from cytotoxic cells of the immune system, as in
Figure 1 [1]. In particular, the extrinsic pathway is activated
upon the binding of specific proapoptotic ligands, namely,
FasL/CD95L and tumor necrosis factor-𝛼 (TNF-𝛼), to their
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Figure 1: TRAIL-receptor mediated signalling pathways. By binding its receptor TRAIL initiates cell death (apoptosis) via either intrinsic
(mitochondria) or extrinsic pathway and/or induces the activation of survival genes resulting in cell proliferation/migration and inhibition
of apoptosis.
transmembrane receptors. This stimulates the trimerization
of the transmembrane receptors and the formation of the
death-inducing signalling complex (DISC), based on the
recruitment of Fas associated death domain (FADD). Subse-
quently, FADD recruits both caspase-8 and caspase-10, which
undergo autoactivation by proteolytic cleavage and which in
turn activate caspase-3, caspase-6, and caspase-7, eventually
executing the apoptotic program (Figure 1).
TRAIL is the third proapoptotic ligand that triggers
the extrinsic pathway. The name TRAIL or TNF-related
apoptosis-inducing ligand was chosen for the high homology
of this protein to other TNF family members [2]. The
percentage of identity with FasL/CD95L and TNF-𝛼 is in fact
28% and 23%, respectively. The gene encoding for TRAIL is
located on chromosome 3 at position 3q26. TRAIL gene locus
spans approximately 20 kb and it has five exonic segments
and four introns. In humans, TRAIL is expressed as a type II
transmembrane protein of 281 amino acids and it is composed
of four parts: an extracellular TNF-like domain, an extracel-
lular stalk, a transmembrane helix, and a small cytoplasmatic
domain. After cleavage at the stalk domain, TRAIL is released
as a soluble molecule with biological activity. It is at this
stage that the cysteine residue at position 230 (Cys230) allows
TRAIL to interact and assemble with other two molecules of
TRAIL forming a trimeric ligand.These TRAIL homotrimers
are proapoptotic agonists that bind to their specific death
receptors on the surface of target cells and induce apoptosis
(Figure 1). Recently, it has been shown that TRAIL can induce
also necroptosis, which is a regulated and programmed
form of necrosis that takes place after TRAIL binding to its
specific death receptors and which can be useful to the
body when apoptosis has been blocked [3, 4]. The human
receptors for TRAIL, however, are not only death receptors
(DR) but also decoy receptors (DcR). DR include TRAIL-R1
(DR4/TNFRSF10A) [5] and TRAIL-R2 (DR5/TNFRSF10B)
[6–9], which are both type I transmembrane proteins con-
taining an intracellular death domain (DD) that classically
stimulates apoptosis upon TRAIL binding. As for DcR, they
include TRAIL-R3 (TRID/DcR1/TNFRSF10C) [10], TRAIL-
R4 (DcR2/TNFRSF10D) [11, 12], and osteoprotegerin (OPG)
[13]. DcR1 and DcR2 are transmembrane receptors that
differ from DR in that their cytoplasmatic domain lacks an
intact DD, while OPG is a soluble receptor that lacks both
transmembrane and cytoplasmatic residues.
2.2. TRAIL Biological Functions. The first and best character-
ized function of TRAIL is its ability to induce apoptosis in
transformed cells, such asmalignant cells. Studies on TRAIL-
knockout mice have in fact demonstrated that mice without
TRAIL are viable and fertile but more susceptible to tumor
metastases, indicating that TRAIL regulates immune surveil-
lance and host defence against tumor initiation and progres-
sion [14, 15]. In particular, TRAIL seems tomediate the ability
of natural killer (NK) cells and cytotoxic T lymphocytes to
block tumor growth and metastasis development [16, 17]. It
should be noted that TRAIL-dependent killing by NK cells is
believed to protect the organism also from infection [18].
Interestingly, one of the unique aspects of TRAIL, as com-
pared to the other proapoptotic ligands [19, 20], is that TRAIL
has the ability to induce apoptosis preferentially in trans-
formed cells, such as tumor or infected cells, while it would
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sparemost normal cells [21]. In particular Ashkenazi and col-
leagues demonstrated that the exposure of cynomolgus mon-
keys to recombinant human (rh) TRAIL at 0.1–10mg/Kg/day
over 7 days did not induce detectable toxicity, whereas, for
comparison, TNF-𝛼 induced severe toxicity at much lower
doses such as 0.003mg/Kg/day [22]. The balance between
TRAIL death and decoy receptors was initially considered a
possible mechanism whereby cells could negatively regulate
TRAIL-induced cytotoxicity, therefore explaining TRAIL
selectivity. However, a correlation between this ratio and
either protection or susceptibility to apoptosis has never been
clearly demonstrated and other mechanisms have been put
forward in order to explain the different sensitivity to TRAIL,
such as the overexpression of c-FLIP, which could interfere
with the activation of caspase-8 [23].
Another intriguing aspect of TRAIL is that it can appar-
entlymediate also nonapoptotic signalling.Amajor contribu-
tion of our group to the biology of the TRAIL/TRAIL-R sys-
temwas the discovery that when TRAIL R1/DR4 and TRAIL-
R2/DR5 bind to TRAIL homotrimers they can stimulate not
only proapoptotic pathways, but also prosurvival pathways,
such as nuclear factor 𝜅B (NF-𝜅B), ERK1/ERK2, and Akt
[24, 25] (Figure 1). In particular the prosurvival signalling
complex would still rely on DISC assembly, but instead of
caspase activation, it would depend on the recruitment of
TNF-receptor-associated death domain (TRADD), TNF-
receptor-associated factor-2 (TRAF2), receptor interacting
protein (RIP), and the inhibitor of 𝜅B kinase (IKK𝛾). Once
this complex has been assembled, it would then activate
NF𝜅B, PI3K/Akt, andMAPKs, including ERK, as well as JNK
and p38, leading to survival signals (Figure 1). It has been
suggested that the ability of TRAIL to activate such opposed
pathways depends on the incorporation of specific intracellu-
lar proteins into “lipid rafts.” Lipid rafts are platforms consist-
ing of a dynamic pool of cholesterol and sphingolipids, which
recruit signalling molecules including cell surface receptors.
Several studies have reported that there is a redistribution
of TRAIL receptors and DISC components from “non-
rafts” into “lipid rafts” and it is current opinion that this is
what could switch either cell apoptosis or survival upon
TRAIL stimulation [26, 27]. Consistent with the concept that
TRAIL triggers nonapoptotic signals in normal cells, we have
recently demonstrated that systemic TRAIL delivery signif-
icantly reduced cardiac fibrosis and apoptosis in a mouse
model of diabetic cardiomyopathy [28].
3. TRAIL and the Immune System
Besides the involvement in tumor surveillance and infection
control, TRAIL seems to critically regulate also the immune
system homeostasis. Animal studies have in fact shown that
genetic loss of both FasL and TRAIL resulted in a condition
that resembles to human autoimmune lymphoproliferative
syndrome (ALPS), which is characterized by splenomegaly
and lymphadenopathy, due to an accumulation of
CD4−CD8− “double negative” T cells [29].The fact that in this
model TRAIL deficiency affected the severity of lymphocyte
accumulation indicates that TRAIL contributes to the control
of peripheral lymphocyte apoptosis, perhaps in a secondary
or cooperative manner with respect to FasL. In addition, the
finding that TRAIL deficiency led to ALPS2 development,
which is characterized by abnormal DC accumulation [23],
suggests that TRAIL helps in getting rid of immature
dendritic cells (DC), by killing them before lymph node
entry.
Moreover, the observation that TRAIL-knockout mice
had a severe defect in thymocyte apoptosis and were hyper-
sensitive to both collagen-induced arthritis and streptozotocin-
induced diabetes initially suggested that TRAIL could be crit-
ically involved in the maintenance of central tolerance by the
negative selection of autoreactive thymocytes [30]. Neverthe-
less, further studies have challenged this hypothesis. Cretney
and colleagues could in fact not reproduce the finding that
negative selection was impaired in TRAIL-knockout mice
[31], nor that the adaptor protein FADD was essential for
thymic negative selection [32]. Eventually, though, Corazza
and colleagues reconciled these conflicting results by suggest-
ing that in the thymus TRAIL is a responsemodifier formito-
chondrial apoptosis rather than a directmechanismof thymic
negative selection [33], therefore implying that TRAIL is
involved, although only indirectly, in thymic apoptosis and
thymic negative selection.
If central tolerance relies on thymic negative selection,
peripheral tolerance is based on (i) anergy induction; (ii) the
presence of regulatory CD4+CD25+ T cells (Treg); and (iii)
the termination of T cell immune responses, which depends
on the activation-induced cell death (AICD). It is in fact
through AICD or by eliminating activated immune cells that
the organism prevents any potential autoimmune damage.
One of the first observations suggesting TRAIL involvement
in mature lymphocyte poststimulation apoptosis was that
TRAIL induced apoptosis in T cells after sensitization with
IL-2 [34]. Subsequently, TRAIL was also found to play a role
in AICD of human peripheral blood mononuclear cells [35],
which is consistent with the concept that this molecule helps
in getting rid of potentially dangerous immune cells. Apart
from AICD, TRAIL seems to regulate peripheral tolerance
also by promoting the proliferation of T regulatory (Treg)
cells [36, 37]. These are cells that play an essential role in
maintaining immune tolerance, and when they are absent,
such as in individuals with IPEX (immune dysregulation,
polyendocrinopathy, enteropathy, and X-linked syndrome),
there is an enhanced susceptibility to autoimmune diseases
and diabetes [38]. In addition to that, the third way whereby
TRAIL could regulate peripheral tolerance is its ability to pre-
vent primary T cell proliferation during the Ag-independent
T cell activation [39].
Interestingly, it seems that TRAIL affects adaptive
immune cells not only by inducing cell death, but also by
inhibiting their activation and expansion [40]. On one hand,
it has been shown that differentiating CD4+ Th1 cells [41]
are selectively removed by TRAIL-mediated apoptosis [42],
which explains why the frequency of CD4+Th1 cells is greater
in TRAIL-knockout mice with respect to their controls [36].
Likewise, also CD8+ Ag-activated T cells, generated in the
absence of CD4+ T cells, are removed by TRAIL-mediated
apoptosis [16]. On the other hand, in CD8+ T cells TRAIL can
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induce cell cycle arrest in G2/Mphase (rather than apoptosis)
[43]. In particular, this effect seems to depend on TRAIL-
mediated cyclin B1 reduction, which would inhibit cyclin B1-
dependent kinase and the transition from G2 to mitosis [44].
Nevertheless, TRAIL can reduce T cell proliferation also by
inhibiting calcium influx, which leads to a downregulation
of cyclin-dependent kinase 4 and to cell cycle progression
blockade [45]. Not surprisingly, TRAIL is also involved in
the regulation of plasma cell homeostasis, where it promotes
apoptosis under specific conditions, which include the loss
of both CD40 expression and NF𝜅B activation [46]. Con-
sistent with this, administration of neutralizing anti-TRAIL
antibodies markedly increases serum autoantibody levels in
autoimmune prone CH3/HeJ gld/gld mice [47].
To complete the picture, TRAIL seems to have also anti-
inflammatory actions. For example, Renshaw and colleagues
demonstrated that neutrophil apoptosis is accelerated by
leucine zipper-tagged TRAIL, which may represent a poten-
tial mechanism of neutrophil clearance at sites of inflam-
mation [48]. Another argument in favour of TRAIL anti-
inflammatory actions is what it does on atherosclerosis [49].
Atherosclerosis should in fact be considered as an inflamma-
tory disease [50], since plaques are nothing but inflammatory
aggregates, resulting from endothelial damage, which pro-
motes subsequent smooth muscle cell migration and prolif-
eration, monocyte-derived macrophage adhesion and accu-
mulation to the site of injury, and fibrous tissue formation.
In in vitro studies, TRAIL significantly reduced leukocyte/
endothelial cell adhesion by downregulating CCL8 and
CXCL10 chemokine expression [51]. In in vivo studies, TRAIL
delivery reduced the extent of aortic atherosclerosis, possibly
by inducing macrophage apoptosis [52], and consistent with
this finding, Di Bartolo and colleagues reported a reduction
in macrophage accumulation in the atherosclerotic plaques
of TRAIL-knockout mice [53].
4. Protective Role of TRAIL against Diabetes
4.1. Type 1DiabetesMellitus and the Immune System. Diabetes
mellitus (DM) refers to a condition of hyperglycemia that can
be further classified into T1DM, primarily due to a lack of
insulin, or T2DM, primarily due to peripheral insulin resis-
tance. Whether it is T1DM or T2DM, the immune system is
now recognized to be crucially involved in the development
and progression of both. T1DM is in fact a T cell-mediated
autoimmune disease or according to Burnet and Mackay
definition, “a condition in which structural or functional
damage is produced by the action of immunologically com-
petent cells or antibodies against normal components of the
body” arising by “the emergence of forbidden clones of T
lymphocytes” [54]. In particular, as depicted in Figure 2(a),
genetic predisposition and unknown environmental factors
lead to the release of 𝛽-cell DNA and antigens that promote
the recruitment ofmacrophages, neutrophils, DC, andB cells,
as well as the formation of autoantibodies in the pan-
creas [55]. These autoantibodies are usually directed against
insulin, insulinoma-associated antigen (IA) 2, 65-kD isoform
of glutamic acid decarboxylase (GAD-65), 𝛽-cell-specific
zinc transporter (Znt8), and islet cell (ICA) 512, which are
not only the major autoantibody targets but also the main
epitopes activating autoreactive T cells [56]. Here DC pick up
antigens and immune complexes by pinocytosis and, upon
activation, migrate to the pancreatic lymph nodes to present
𝛽-cell antigens to an abnormal number of autoreactive T cells,
which are there because of a defective immune tolerance.
Then, autoreactive T cells become fully activated and home
into the islets. It has to be noted that usually T cells can be
activated by the recognition of autoantigens through MHC
class II on antigen-presenting cells and/or through MHC
class I on𝛽-cells [57, 58].Then, oneway or the other, activated
CD8+ T cells will destroy the 𝛽-cells by the release of cytolytic
granules containing perforins and granzymes or by FasL-
dependent interactions, while CD4+ release proinflammatory
cytokines (Figure 2(a)). At the same time, inflammation and
tissue damage are further worsened by an impairment of
Treg cells, which seem to be either lacking [59] and/or
defective [60] in T1DM. As for the natural history of the
disease, this islet inflammation (or insulitis) generally pre-
cedes T1DM onset [61] and it corresponds to the stage where
autoantibodies are detectable [62]. Of note, neither autoan-
tibodies nor B cells seem to be critically involved in T1DM
pathogenesis, as T1DM can affect patients with X-linked
agammaglobulinemia [63]. Anyway, when 70–80% of 𝛽-cells
have been destroyed, the residual insulin-producing cells are
insufficient to maintain glucose tolerance and T1DM devel-
ops [64].
4.2. TRAIL and T1DM. Interestingly, experimental evidence
suggests that TRAIL might protect against T1DM [65]. In the
first animal study exploring this issue, TRAIL blockade by
sDR5 injection significantly increased T1DM incidence and
accelerated T1DM onset in NOD (nonobese diabetic) mice
[66]. Moreover, in this study sDR5 injection led to a greater
islet inflammation and it increased T cell proliferation as well
as anti-GAD-65 levels [66]. Likewise, a second experiment
showed that TRAIL deficiency worsened streptozotocin pro-
diabetogenic effects, since T1DM incidence and progression
increased significantly in TRAIL-knockout mice [66]. Then,
in the thirdwork of the series, we showed that TRAIL delivery
in streptozotocin-injected rats preserved pancreatic islets and
significantly ameliorated the severity of T1DM, by lowering
glucose levels [67]. These experimental findings are in line
with the clinical observation that TRAIL circulating levels not
only are decreased in T1DM patients but also are negatively
correlated with patient insulin requirement, and the lowest
levels of TRAIL are observed in those patients with diabetic
ketoacidosis at onset [68].
Nevertheless, the mechanisms whereby TRAIL could
defend from T1DM development and progression remain to
be fully clarified. One hypothesis accounting for TRAIL
protection against T1DM is that it could induce T cell death or
inhibit their activation (Figure 2(b)). This has been partly
confirmed by Mi and colleagues who showed that TRAIL
suppressed the proliferation of autoreactive T cells isolated
from diabetic NOD mice [69]. Here TRAIL upregulated p27
expression, which stops T cell cycle progression, and simulta-
neously inhibited IL-2, which on the contrary would promote
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Figure 2: Current immunological view of T1DM and T2DM. (a) Islet inflammation in T1DM.A triggering insult recruits antigen-presenting
cells (dendritic cells, macrophages, and B cells). Dendritic cells (DC) pick up self-antigens and immune complexes by pinocytosis and carry
them to the pancreatic draining lymph nodes where they present them to autoreactive T cells and activate them. Such T cells migrate
back to the islets where they destroy 𝛽-cells either by perforin, granzymes, or FasL-dependent interactions (CD8+), or by proinflammatory
cytokine release (CD4+). Macrophages and B cells can also act as antigen-presenting cells. The cross-talk between B and T cells promotes
the development of plasma cells, the release of autoantibodies, and the formation of immune complexes, which all together create a vicious
cycle of inflammation and death. (b) TRAIL effects on islet inflammation. Experimental studies have shown that TRAIL inhibits T cell
proliferation/expansion, induces T cell death, promotes Treg expansion, and protects 𝛽-cells. (c) Overview on obesity-induced insulin
resistance. Obesity increases free fatty acids (FFA) that bind to toll-like receptor 4 (TLR-4) and activate adipose tissue macrophages. At the
same time, the expansion of the adipose tissue, which outgrows its vascular supply, induces adipocyte necrosis, which stimulates macrophage
recruitment and activation. One recruiting factor is CCL2, which mediates the recruitment of CCR2 monocytes, which differentiate into
macrophages. Adipocyte death and innate immune cell activation stimulate the migration of adaptive immune cells. In addition, macrophage
migration to the adipose tissue and their activation induce the expression of proinflammatory molecules, such as IL-6, MCP-1, TNF-𝛼,
and other adipokines which lead to insulin resistance. Peripheral insulin resistance is featured by impaired glucose uptake, increase of
gluconeogenesis, hyperlipidemia, hyperglycemia, 𝛽-cell hypertrophy, 𝛽-cell inflammation, stress, and death. (d) TRAIL effects on obesity-
induced insulin resistance. Experimental studies show that TRAIL reduces fat mass gain, systemic and tissue proinflammatory cytokines, and
ameliorates peripheral insulin resistance. This is associated to a reduction of 𝛽-cell hypertrophy, inflammation, and loss.
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p27 degradation and cell cycle progression [70]. Another
hypothesis is that TRAIL could promote 𝛽-cell survival. In
vitro experiments have confirmed that exposure to TRAIL
does not affect𝛽-cell viability in rat insulinoma cells. Here, on
the contrary, TRAIL upregulates DcR1, which should prevent
apoptosis [71] and has been interpreted as a defensive strategy
of 𝛽-cells against infiltrating leukocytes [72]. In addition to
that, TRAIL can induce the elevation of tissue inhibitor of
metalloproteinase-1 (TIMP-1) [73], whose increase might
protect against T1DMby reducingMMP-9 pancreatic activity
[73], which cleaves insulin and is generally higher in diabetic
patients [74–76]. This is consistent not only with in vitro
experiments showing that the addition of TIMP-1 signifi-
cantly reduces insulinoma cell death [73], but also with the
finding that TIMP-1 prevents cytokine-mediated dysfunction
and cytotoxicity in pancreatic islets and 𝛽-cells [77].
4.3. Type 2 Diabetes Mellitus and the Immune System. If
T1DM is primarily an adaptive immune system-mediated
autoimmune disease affecting the endocrine pancreas, T2DM
and its complications seem to result – at least initially- from
an activation of the innate immune system in the organs
involved in glucose metabolism [78]. The theory that inflam-
mation is involved in T2DM is in fact not new but dates back
as far as to the end of the ninetieth century, when Ebstein
reported that high doses of salicylate improved glycosuria in
diabetic patients [79]. This theory was then abandoned until
Pickup and Crook observed that the dyslipidemia found in
T2DM patients (low HDL cholesterol and high triglycerides)
is typically seen also in patients with acute-phase reactions
and they put forward that lifestyle and the environment may
cause T2DM in individuals with hypersensitive acute-phase
response [80]. In line with these early observations, the
current view on the human immunology of T2DM [81] is that
inflammation links obesity to T2DM [81], as it mediates the
development of obesity-induced insulin resistance in insulin
target organs [82].The first direct evidence of the connection
existing between obesity, inflammation, and T2DM has been
the elevation of TNF-𝛼, a well-known proinflammatory
molecule, in the plasma and adipose tissue of obese rodents,
whose levels were proportional to insulin resistance, whose
blockade ameliorated insulin sensitivity [83] and whose
delivery recapitulated insulin resistance [84]. Consistent with
it, also C-reactive protein, which is an unspecific measure of
immune system activation, not only is associated with obesity
[85] but also predicts [86] and/or identifies the people at risk
of developing T2DM [87]. In line with these findings, we have
recently shown that in high-fat diet fed mice, which become
obese, there is not only an elevation of proinflammatory
cytokines, but also of the TRAIL decoy receptor OPG, which
promotes inflammatory changes and glucose abnormalities
once it is delivered in control mice [88].
The explanation as to why obesity is associated with a
prominent inflammatory response relies on the changes
occurring in the white adipose tissue, which should be
considered as an endocrine organ that changes its secretory
patternwhen it enlarges [89]. In particular, in obesity, fatmass
expansion causes adipocyte hypoxia and necrosis because
the adipose tissue outgrows its vascular supply. These events
promote the secretion of proinflammatorymolecules [90, 91],
which all together stimulate macrophage recruitment and
activation [82, 90, 92]. In addition to that, it has also been
shown that in the fat of obese subjects there is an increased
activity of 11𝛽-hydroxysteroid dehydrogenase type 1 [93, 94],
whose overexpression leads to proinflammatory changes in
the adipocyte expression profile and to an increase in the
number of macrophages [92]. It is macrophage infiltration
into the expanding adipose tissue that is considered one of the
key steps towards insulin resistance and T2DM development
[95]. Once macrophages home to the inflamed fat mass,
circulating and tissue proinflammatory cytokines increase,
which will inhibit insulin signalling in peripheral tissues,
leading to obesity-related insulin resistance (Figure 2(c))
[96]. Consistent with it, high-fat diet fedmice lacking theC-C
motif chemokine receptor-2 that is essential for macrophage
recruitment exhibited fewer macrophages and a lower
inflammatory gene profile in the adipose tissue as well as
reduced insulin resistance [97]. Conversely, mice overex-
pressing MCP-1 in their adipose tissue showed the opposite
phenotype [98]. At this stage, the inflamed fatmass stimulates
the migration of T and B cells, both contributing to insulin
resistance [99]. Obesity-related insulin resistance, however,
affects not only adipose tissue but also all insulin target
organs. In the fat lipolysis and free fatty acid (FFA) levels
increase, stimulating tissue inflammation and damage, for
example, by activating toll-like receptor 4 (TLR-4) [100],
while in the liver gluconeogenesis increases and in skeletal
muscle glucose uptake is reduced.Hyperlipidemia and hyper-
glycemia stimulate𝛽-cell hypertrophy and hyperinsulinemia,
ultimately leading to 𝛽-cell stress, exhaustion, inflammation,
and T2DM.
4.4. TRAIL and T2DM. Animal studies suggest that TRAIL
might protect against T2DM too. Di Bartolo and colleagues
found that TRAILdeficiency promoted diabetes development
in ApoE/TRAIL-knockout mice put on a high-fat diet [53],
which is commonly used to induce obesity and insulin
resistance in rodents [88, 101, 102]. In particular, ApoE/
TRAIL-knockout mice displayed significantly higher glucose
levels and lower insulin levels than ApoE-knockout mice.
Consequently, this study showed that TRAIL deficiency sig-
nificantlyworsened glucose tolerance, and this was associated
with 𝛽-cell function impairment, 𝛽-cell density reduction,
and an increase in islet macrophage infiltration. Consistent
with this we have documented the ability of TRAIL to signifi-
cantly reverse themetabolic abnormalities due to an oversup-
ply of lipids and thus to slow down the natural progression
of T2DM [101]. In particular, we studied 27 male C57Bl6J
mice randomly allocated to standard diet (SD), high-fat
diet (HF), and high-fat diet + TRAIL (HF + TRAIL) for 12
weeks. TRAIL was delivered weekly by intraperitoneal injec-
tion at a dose of 10 𝜇g per mouse. At the end of the study we
found that TRAIL treatment reduced significantly the hyper-
glycemia and the hyperinsulinemia displayed by the high-fat
diet fed mice during an IPGTT. Moreover, TRAIL treatment
significantly reduced the 𝛽-cell hypertrophy and the 𝛽-cell
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Figure 3: TRAIL reduces 𝛽-cell mass and increases 𝛽-cell density in the islets of HFD fed mice. Quantification of mass and density and
representative histological sections of pancreas islets from standard diet (SD), high-fat diet (HF), or high-fat diet fedmice treated with TRAIL
(HF + TRAIL) (magnification 40x). The sections were stained with polyclonal antibody against insulin (3,3󸀠-diaminobenzidine-DAB) and
counterstained with hematoxylin. Pancreatic 𝛽-cell mass was estimated by multiplying the mean density of staining for insulin in the islet
section by the mean islet area per area of pancreas. This was expressed in arbitrary units adjusted for the wet weight of the pancreas of each
mouse. Pancreatic 𝛽-cell density was estimated by determining the percentage proportion of islet area occupied by the brown (DAB) staining
and was expressed as percentage stained area. Data are mean ± SEM ∗𝑃 < 0.05 versus SD; #𝑃 < 0.05 versus HF.
loss, as it reduced 𝛽-cell mass and increased 𝛽-cell density
(Figure 3). This was associated with a decrease in protein
nitrosylation (data not shown), as well as with a significant
reduction in CD3 infiltration (Figure 4) in the islets of
TRAIL treated high-fat diet fed mice. This is of relevance
since lymphocyte-driven autoimmune assault is one of the
mechanisms accounting for 𝛽-cell destruction in T2DM [96].
Interestingly, we have also shown that OPG, which is TRAIL
decoy receptor, has opposite actions to those of TRAIL, as it
seems to promote glucose intolerance [88, 103].
The mechanisms underlying TRAIL protection against
T2DM development may include some antiadipogenic and
anti-inflammatory effects of this molecule (Figure 2(d)).
Going back to the adipose tissue, the demonstration that its
removal improves insulin resistance highlights the crucial
role that the fat plays in the development of obesity-induced
insulin resistance and T2DM [104]. So, the first mechanism
whereby TRAIL could protect against T2DM is its effect
on adiposity. In our study TRAIL significantly reduced the
deposition of fat mass induced by the high-fat diet [101], due
to proapoptotic and antiadipogenic actions, as it induced the
expression of caspase-3while it inhibited that of PPAR-𝛾.This
is consistent with what has been reported by Di Bartolo and
colleagues, who found that mice lacking TRAIL presented
an increased deposition of fat [53]. Moreover, human studies
show that there is a correlation between circulating TRAIL
and body mass [105], which may be interpreted as a compen-
satory mechanism set up by the body to respond to fat gain
and which in any case reinforces the notion that TRAIL is
linked to body weight regulation. In the second place, TRAIL
has also the ability to put out inflammation, which may be
the consequence of its antiadipogenic actions, or of its effects
on the immune system. In particular, we found that TRAIL
significantly reduced systemic and tissue IL-6, MCP-1, and
TNF-𝛼 [101], which on the contrary were elevated in TRAIL
deficient mice [53]. This could explain the reduction in islet
CD3 cells that we observed in TRAIL treated mice and the
amelioration of their metabolic abnormalities.
5. Conclusion
There is abundant literature showing that TRAIL is involved
not only in tumor growth suppression and/or infection
control, but also in the regulation of both innate and adaptive
immune system. Recently, a few in vivo studies have demon-
strated that TRAIL might protect against the development
and/or progression of diabetes. Therefore, since the immune
system is crucially involved in diabetes development, it is
through its action on innate and adaptive immunity that
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Figure 4: TRAIL reducesCD3 infiltration. CD3 count and representative histological sections of pancreas islets from standard diet (SD), high-
fat diet (HF), or high-fat diet fed mice treated with TRAIL (HF + TRAIL) (magnification 20x). The sections were stained with polyclonal
antibody against CD3 (3,3󸀠-diaminobenzidine-DAB) and counterstained with hematoxylin. Pancreatic CD3 infiltration was estimated by
determining the total number of cells positive for CD3 per islet. Data are mean ± SEM ∗𝑃 < 0.01 versus SD; #𝑃 < 0.01 versus HF.
TRAIL is likely to protect against diabetes. TRAIL is in fact
involved in the regulation of central and peripheral tolerance,
mediates T cell death and inhibits their proliferation, and
promotes Treg cells. As for T2DM, TRAIL seems to prevent
fat mass enlargement and exerts anti-inflammatory actions,
whereby it could ameliorate the metabolic abnormalities
typical of obesity-induced insulin resistance. The idea that
this molecule could kill what is leading/contributing to dia-
betes, such as activated immune cells, macrophages, or even
adipocytes, and protect normal 𝛽-cells is truly fascinating.
Nevertheless further in vivo studies are needed to clarify the
extent of TRAIL actions and further in vitro studies in order
to clarify its precise mechanisms of action.
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